国药股份
(600511)
| 流通市值：193.34亿 | | | 总市值：263.62亿 |
| 流通股本：5.53亿 | | | 总股本：7.55亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,122,142,562.33 | 49,696,045,528.87 | 36,529,666,779.32 | 24,140,175,654.64 |
| 营业收入 | 12,122,142,562.33 | 49,696,045,528.87 | 36,529,666,779.32 | 24,140,175,654.64 |
| 二、营业总成本 | 11,584,004,995.37 | 47,194,088,893.72 | 34,802,634,590.56 | 23,008,252,688.98 |
| 营业成本 | 11,270,055,777.5 | 45,704,776,081.97 | 33,702,076,932.63 | 22,274,144,953.03 |
| 税金及附加 | 26,821,986.63 | 114,735,965.78 | 81,011,852.43 | 46,021,193.37 |
| 销售费用 | 201,454,461.53 | 962,378,292.42 | 681,548,681.79 | 474,511,597.32 |
| 管理费用 | 100,533,956.36 | 467,127,883.37 | 307,982,951.62 | 201,609,496.26 |
| 研发费用 | 13,941,626.51 | 71,197,375.91 | 53,170,617.46 | 34,337,438.64 |
| 财务费用 | -28,802,813.16 | -126,126,705.73 | -23,156,445.37 | -22,371,989.64 |
| 其中:利息费用 | 7,317,404 | 31,570,183.83 | 35,157,666.75 | 25,789,027.11 |
| 其中:利息收入 | 39,711,214.35 | 166,372,000.83 | 70,035,701.58 | 54,868,607.43 |
| 加:公允价值变动收益 | - | 10,817,458.31 | 34,725,094.18 | 34,725,094.18 |
| 加:投资收益 | 104,978,672.01 | 358,951,819.35 | 286,976,822.59 | 197,452,278.72 |
| 资产处置收益 | -2,372.8 | 83,443.4 | 332,133.05 | 460,355.57 |
| 资产减值损失(新) | -2,793,539.68 | 388,870.07 | -21,560,637.27 | -9,440,883.24 |
| 信用减值损失(新) | -30,175,806.35 | -9,165,197.93 | -48,621,366.11 | -40,010,474.57 |
| 其他收益 | 3,654,314.4 | 81,324,762.7 | 14,916,455.04 | 7,896,488.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 613,798,834.54 | 2,944,357,791.05 | 1,993,800,690.24 | 1,323,005,824.36 |
| 加:营业外收入 | 629,908.19 | 3,005,515.94 | 2,927,145.82 | 1,867,986.71 |
| 减:营业外支出 | 892,265.98 | 16,473,062.04 | 10,673,919.96 | 365,565.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 613,536,476.75 | 2,930,890,244.95 | 1,986,053,916.1 | 1,324,508,245.18 |
| 减:所得税费用 | 118,418,009.37 | 596,419,504.34 | 404,143,051.26 | 261,831,491.13 |
| 六、净利润 | 495,118,467.38 | 2,334,470,740.61 | 1,581,910,864.84 | 1,062,676,754.05 |
| 持续经营净利润 | 495,118,467.38 | 2,334,470,740.61 | 1,581,910,864.84 | 1,062,676,754.05 |
| 归属于母公司股东的净利润 | 459,454,518.02 | 2,145,998,746.54 | 1,462,295,886.22 | 984,583,170.5 |
| 少数股东损益 | 35,663,949.36 | 188,471,994.07 | 119,614,978.62 | 78,093,583.55 |
| (一)基本每股收益 | 0.61 | 2.84 | 1.94 | 1.3 |
| (二)稀释每股收益 | 0.61 | 2.84 | 1.94 | 1.3 |
| 八、其他综合收益 | -5,853,233.88 | 5,102,617.31 | 1,013,059.71 | 759,794.78 |
| 归属于母公司股东的其他综合收益 | -5,853,233.88 | 5,102,617.31 | 1,013,059.71 | 759,794.78 |
| 九、综合收益总额 | 489,265,233.5 | 2,339,573,357.92 | 1,582,923,924.55 | 1,063,436,548.83 |
| 归属于母公司股东的综合收益总额 | 453,601,284.14 | 2,151,101,363.85 | 1,463,308,945.93 | 985,342,965.28 |
| 归属于少数股东的综合收益总额 | 35,663,949.36 | 188,471,994.07 | 119,614,978.62 | 78,093,583.55 |
| 公告日期 | 2024-04-26 | 2024-03-21 | 2023-10-25 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |